Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Chinese Patent Office
Julphar
Colorcon
Accenture
Farmers Insurance
Moodys
US Army
Fish and Richardson

Generated: December 10, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 062055

« Back to Dashboard

NDA 062055 describes ERYTHROMYCIN ETHYLSUCCINATE, which is a drug marketed by Ani Pharms Inc, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Arbor Pharms Llc, Barr, and Mylan, and is included in eleven NDAs. It is available from two suppliers. Additional details are available on the ERYTHROMYCIN ETHYLSUCCINATE profile page.

The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
Summary for 062055
Tradename:ERYTHROMYCIN ETHYLSUCCINATE
Applicant:Ani Pharms Inc
Ingredient:erythromycin ethylsuccinate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 062055
Suppliers and Packaging for NDA: 062055
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 062055 ANDA ANI Pharmaceuticals, Inc. 62559-440 62559-440-01 100 mL in 1 BOTTLE (62559-440-01)
ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 062055 ANDA ANI Pharmaceuticals, Inc. 62559-440 62559-440-02 200 mL in 1 BOTTLE (62559-440-02)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrengthEQ 200MG BASE/5ML
Approval Date:Approved Prior to Jan 1, 1982TE:AB1RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrengthEQ 400MG BASE/5ML
Approval Date:Nov 2, 2018TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:GRANULE;ORALStrengthEQ 200MG BASE/5ML
Approval Date:Nov 2, 2018TE:AB2RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Cerilliant
US Army
Dow
McKesson
Medtronic
Harvard Business School
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.